Tempest Therapeutics (NASDAQ:TPST) Posts Earnings Results, Beats Expectations By $0.11 EPS

Tempest Therapeutics (NASDAQ:TPST) issued its quarterly earnings results on Friday. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.11, Zacks reports.

Tempest Therapeutics Stock Down 0.3%

TPST traded down $0.00 during trading hours on Friday, hitting $0.38. The stock had a trading volume of 153,050 shares, compared to its average volume of 219,555. The company’s fifty day simple moving average is $0.68 and its 200 day simple moving average is $1.39. Tempest Therapeutics has a 1 year low of $0.34 and a 1 year high of $9.75. The stock has a market cap of $7.64 million, a PE ratio of -0.09 and a beta of -1.54.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Friday, October 9th. Wall Street Zen upgraded shares of Tempest Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Tempest Therapeutics currently has a consensus rating of “Reduce”.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical-stage biotechnology company focused on developing treatments for cancer. The company’s research centers on small-molecule medicines designed to affect biological pathways involved in tumor growth and the immune response. Its lead candidate, TPST-1120, is an oral inhibitor of PPARα that has been studied for advanced liver cancer, including in combination with other cancer therapies. Tempest has also worked on additional drug candidates targeting immune-related pathways.